Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757869 · ClinicalTrials.gov registry record · Phase 3
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 20,284
- Enrollment target
- 20
- Study locations
NCT05757869: Active Phase 3 study of Atrial Fibrillation, sponsored by Janssen Research & Development.
NCT05757869 is a Phase 3 study of Atrial Fibrillation that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 20,284 participants, above the 2,896-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (600% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757869, a Phase 3 study of Atrial Fibrillation, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 20,284 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Primary Outcome
Time to the first occurrence of composite endpoint of stroke and non-CNS systemic embolism will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apixaban
- DRUG Milvexian
- DRUG Apixaban Placebo
Study Locations (20)
California
- Bakersfield Memorial Hospital - Bakersfield
- Vitality Clinical Research - Beverly Hills
- Chula Vista Cardiac Clinic - Chula Vista
- Sharp Chula Vista Medical Center - Chula Vista
- Mission Cardiovascular Research Institute - Fremont
- Paradise Clinical Research Group LLC - Glendora
- Miller Children's at Long Beach Medical Center - Long Beach
- Los Angeles Cardiology Associates - Los Angeles
- University of Southern California - Los Angeles
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- Ascension St. Vincent's Health System - Birmingham
- SEC Clinical Research - Dothan
- HH Heart Center and Heart Center - Huntsville
- CB Flock Research Corporation - Mobile
Arizona
- Mercy Gilbert Medical Center - Gilbert
- Valleywise Health Medical Center - Phoenix
- Arizona Arrhythmia Research Center - Phoenix
- Arizona Heart Hospital - Phoenix
- HonorHealth Neurology - Scottsdale
Arkansas
- Arkansas Heart Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,284 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
What the registry record for NCT05757869 still lists
NCT05757869 is an interventional study that assigns participants to a tested intervention. Its 20,284 participants enrollment target places it among the larger protocols in the corpus, above the 2,896-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (600% higher).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05757869 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05757869 about?
NCT05757869 is a clinical study titled "A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation". The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
What is the current status of trial NCT05757869?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 20,284 participants. The study started on 2023-04-11. Estimated completion is 2026-10-31.
What conditions does trial NCT05757869 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT05757869?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG), Milvexian (DRUG), Apixaban Placebo (DRUG).
Who is sponsoring clinical trial NCT05757869?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757869 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05757869's enrollment target sits among peer trials
20,284 6th of 202 higher than 197 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062342 · 20,400 participants · NA
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI